Recent Updates
Recently added Catalysts

urapidil

Phase 3

Stroke, Acute | Small molecule | Neurology |China Pharma Holdings, Inc.|Last Updated: Mar 26, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedNO_TREATMENT_CONTROLLEDDMC
Total Trials1
Total Enrollment2,425
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03790800Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke TrialPHASE3 COMPLETED 2,425Mar 20, 2020Nov 30, 2023Mar 26, 20254 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
level of physical function
Day 90

Level of function defined across 7 categories of disability on the modified Rankin scale (mRS 0-6) in which scores of 0 or 1 indicate good function without or with symptoms but not disability, socress of 2 indicates slight disability but independence, 3 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

Secondary Endpoints
number of patients with serious adverse events
Day 90
number of patients with any intracranial hemorrhage
Day 7
size of cerebral infarction
Day 2
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Intervention groupEXPERIMENTALIf systolic blood pressure\>180:IV Urapidil 25mg If systolic blood pressure\>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)
control groupNO_INTERVENTIONTo receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is \>220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.
Interventions
NameTypeDescription
urapidilDRUGA standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: 1. age ≥18 years; 2. Acute syndrome that is due to presumed acute stroke, defined as FAST(Face, Arm, Speech, Time) scores of ≥2 with an arm motor deficit and time ≤2 hours from last seen well; 3. Systolic BP ≥150 4. Able to provide brief informed consent (if a waver of consent i...

Countries:China
Unlock Eligibility Criteria